These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10216436)

  • 21. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
    Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
    Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain.
    Imai S; Narita M; Hashimoto S; Nakamura A; Miyoshi K; Nozaki H; Hareyama N; Takagi T; Suzuki M; Narita M; Suzuki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):183-92. PubMed ID: 17240843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic morphine-induced loss of the facilitative interaction between vasoactive intestinal polypeptide and delta-opioid: involvement of protein kinase C and phospholipase Cbetas.
    Liu NJ; Chakrabarti S; Gintzler AR
    Brain Res; 2004 Jun; 1010(1-2):1-9. PubMed ID: 15126111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
    Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
    Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human experimental pain models in drug development: translational pain research.
    Arendt-Nielsen L; Curatolo M; Drewes A
    Curr Opin Investig Drugs; 2007 Jan; 8(1):41-53. PubMed ID: 17263184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
    Ruiz F; Fournié-Zaluski MC; Roques BP; Maldonado R
    Br J Pharmacol; 1996 Sep; 119(1):174-82. PubMed ID: 8872371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions between opioid-peptides-containing pathways and GABA(A)-receptors-mediated systems modulate panic-like-induced behaviors elicited by electric and chemical stimulation of the inferior colliculus.
    Calvo F; Coimbra NC
    Brain Res; 2006 Aug; 1104(1):92-102. PubMed ID: 16797498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pain control: opioid dosing, population kinetics and side-effects.
    Simons SH; Anand KJ
    Semin Fetal Neonatal Med; 2006 Aug; 11(4):260-7. PubMed ID: 16621750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of antalgic drugs].
    Dubray C
    Therapie; 1999; 54(1):135-45. PubMed ID: 10216437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tapentadol (Nucynta)--a new analgesic.
    Med Lett Drugs Ther; 2009 Aug; 51(1318):61-2. PubMed ID: 19661853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
    Gallantine EL; Meert TF
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pain therapy: from theoretical research to clinical application.
    Camu F; Schneider I
    Acta Anaesthesiol Belg; 1987; 38(2):169-74. PubMed ID: 2889312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application.
    Ehrenpreis S
    Subst Alcohol Actions Misuse; 1982; 3(4):231-9. PubMed ID: 6301083
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological and human studies with a highly potent opioid peptide, D-Met2, Pro5-enkephalinamide.
    Székely JI; Dunai-Kovács Z; Miglécz E; Polgár K; Török K; Földes J; Váradi A; Bános C; Karczag I; Tolna J
    Pol J Pharmacol Pharm; 1987; 39(5):641-56. PubMed ID: 3333615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction.
    Roques BP; Noble F
    NIDA Res Monogr; 1995; 147():104-45. PubMed ID: 8742783
    [No Abstract]   [Full Text] [Related]  

  • 39. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways.
    Wisner A; Dufour E; Messaoudi M; Nejdi A; Marcel A; Ungeheuer MN; Rougeot C
    Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17979-84. PubMed ID: 17101991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of enkephalin-degrading enzymes as potential therapeutic agents.
    Patel A; Smith HJ; Sewell RD
    Prog Med Chem; 1993; 30():327-78. PubMed ID: 8303036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.